• Publications
  • Influence
Body mass index predicts discontinuation due to ineffectiveness and female sex predicts discontinuation due to side‐effects in patients with psoriasis treated with adalimumab, etanercept or
Predictors for successful treatment are important for personalized medicine. Predictors for drug survival of biologics in psoriasis have been assessed, but not split for different biologics or for
Levels of skin-derived antileukoproteinase (SKALP)/elafin in serum correlate with disease activity during treatment of severe psoriasis with cyclosporin A.
Investigating whether SKALP/elafin levels in serum and urine of psoriatic patients can be used as a marker for disease activity during treatment found it to be a tool for monitoring disease activity.
Variant of odontoonychodermal dysplasia?
In this case report we describe a patient with all the manifestations seen in the odontoonychodermal dysplasia syndrome, except for the shape of teeth and mild mental deficiency. © 1995 Wiley-Liss,
Satisfaction of treatment with biologics is high in psoriasis: results from the Bio‐CAPTURE network
Although the effectiveness of biologics for psoriasis has been measured extensively with objective outcome measures, studies based on subjective, patient‐reported outcome measures remain scarce.
Female patients are less satisfied with biological treatment for psoriasis and experience more side‐effects than male patients: results from the prospective BioCAPTURE registry
Female sex has been reported as a predictor for treatment discontinuation with biological therapies for psoriasis, although reasons remain unclear. It can be hypothesized that lower satisfaction with
‘Happy’ drug survival of adalimumab, etanercept and ustekinumab in psoriasis in daily practice care: results from the BioCAPTURE network
Drug survival is a marker for treatment success and dermatological quality‐of‐life measures to drug survival have been published but analysis of these measures is lacking.
Comparison of the 1‐ and 5‐year effectiveness of adalimumab, etanercept and ustekinumab in patients with psoriasis in daily clinical practice: results from the prospective BioCAPTURE registry
The efficacy of etanercept and ustekinumab in psoriasis has been compared in one randomized controlled trial. Comparison of the long‐term effectiveness of biologics in daily‐practice psoriasis
A retrospective study of the teratogenicity of dermatological coal tar products.
A retrospective pilot study among women with psoriasis or dermatitis, who had been treated with tar products between 1981 and 1985, when their age varied between 18 and 35 years, found no literature regarding the possible foetotoxic effects of CCT-products in humans.
Frequency and predictors of a high clinical response in patients with psoriasis on biological therapy in daily practice: results from the prospective, multicenter BioCAPTURE cohort
It is important to assess which patients with psoriasis are more likely to achieve high clinical responses on biologics.